Literature DB >> 21366476

The ClinicalTrials.gov results database--update and key issues.

Deborah A Zarin1, Tony Tse, Rebecca J Williams, Robert M Califf, Nicholas C Ide.   

Abstract

BACKGROUND: The ClinicalTrials.gov trial registry was expanded in 2008 to include a database for reporting summary results. We summarize the structure and contents of the results database, provide an update of relevant policies, and show how the data can be used to gain insight into the state of clinical research.
METHODS: We analyzed ClinicalTrials.gov data that were publicly available between September 2009 and September 2010.
RESULTS: As of September 27, 2010, ClinicalTrials.gov received approximately 330 new and 2000 revised registrations each week, along with 30 new and 80 revised results submissions. We characterized the 79,413 registry and 2178 results of trial records available as of September 2010. From a sample cohort of results records, 78 of 150 (52%) had associated publications within 2 years after posting. Of results records available publicly, 20% reported more than two primary outcome measures and 5% reported more than five. Of a sample of 100 registry record outcome measures, 61% lacked specificity in describing the metric used in the planned analysis. In a sample of 700 results records, the mean number of different analysis populations per study group was 2.5 (median, 1; range, 1 to 25). Of these trials, 24% reported results for 90% or less of their participants.
CONCLUSIONS: ClinicalTrials.gov provides access to study results not otherwise available to the public. Although the database allows examination of various aspects of ongoing and completed clinical trials, its ultimate usefulness depends on the research community to submit accurate, informative data.

Entities:  

Mesh:

Year:  2011        PMID: 21366476      PMCID: PMC3066456          DOI: 10.1056/NEJMsa1012065

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  19 in total

1.  ICH harmonized tripartite guideline: Guideline for Good Clinical Practice.

Authors: 
Journal:  J Postgrad Med       Date:  2001 Jan-Mar       Impact factor: 1.476

2.  Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research.

Authors:  An-Wen Chan; Karmela Krleza-Jerić; Isabelle Schmid; Douglas G Altman
Journal:  CMAJ       Date:  2004-09-28       Impact factor: 8.262

3.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  Ann Intern Med       Date:  2010-03-24       Impact factor: 25.391

4.  Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.

Authors:  Gregory D Curfman; Stephen Morrissey; Jeffrey M Drazen
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

5.  Essie: a concept-based search engine for structured biomedical text.

Authors:  Nicholas C Ide; Russell F Loane; Dina Demner-Fushman
Journal:  J Am Med Inform Assoc       Date:  2007-02-28       Impact factor: 4.497

6.  Medicine. Moving toward transparency of clinical trials.

Authors:  Deborah A Zarin; Tony Tse
Journal:  Science       Date:  2008-03-07       Impact factor: 47.728

7.  Outcome reporting in industry-sponsored trials of gabapentin for off-label use.

Authors:  S Swaroop Vedula; Lisa Bero; Roberta W Scherer; Kay Dickersin
Journal:  N Engl J Med       Date:  2009-11-12       Impact factor: 91.245

8.  Ethics and clinical research.

Authors:  H K Beecher
Journal:  N Engl J Med       Date:  1966-06-16       Impact factor: 91.245

9.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

10.  Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis.

Authors:  Joseph S Ross; Gregory K Mulvey; Elizabeth M Hines; Steven E Nissen; Harlan M Krumholz
Journal:  PLoS Med       Date:  2009-09-08       Impact factor: 11.069

View more
  226 in total

1.  Comparison of Clinical Trial and Systematic Review Outcomes for the 4 Most Prevalent Eye Diseases.

Authors:  Ian J Saldanha; Kristina Lindsley; Diana V Do; Roy S Chuck; Catherine Meyerle; Leslie S Jones; Anne L Coleman; Henry D Jampel; Kay Dickersin; Gianni Virgili
Journal:  JAMA Ophthalmol       Date:  2017-09-01       Impact factor: 7.389

Review 2.  Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.

Authors:  M Angelyn Bethel; Harald Sourij
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

3.  Using health information technology to engage communities in health, education, and research.

Authors:  Lisa K Marriott; David A Nelson; Shauntice Allen; Karen Calhoun; Christina E Eldredge; Kim S Kimminau; Robert J Lucero; Fernando Pineda-Reyes; Bernice B Rumala; Arti P Varanasi; June S Wasser; Jackilen Shannon
Journal:  Sci Transl Med       Date:  2012-02-01       Impact factor: 17.956

4.  Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.

Authors:  Daniel M Hartung; Deborah A Zarin; Jeanne-Marie Guise; Marian McDonagh; Robin Paynter; Mark Helfand
Journal:  Ann Intern Med       Date:  2014-04-01       Impact factor: 25.391

5.  Secular trends in success rate of catheter ablation for atrial fibrillation: The SMASH-AF cohort.

Authors:  Alexander C Perino; George C Leef; Andrew Cluckey; Fahd N Yunus; Mariam Askari; Paul A Heidenreich; Sanjiv M Narayan; Paul J Wang; Mintu P Turakhia
Journal:  Am Heart J       Date:  2018-10-29       Impact factor: 4.749

6.  Association between pediatric clinical trials and global burden of disease.

Authors:  Florence T Bourgeois; Karen L Olson; John P A Ioannidis; Kenneth D Mandl
Journal:  Pediatrics       Date:  2013-12-16       Impact factor: 7.124

7.  Publishing "Invisible" and "Abandoned" clinical trials: a commitment for CTS.

Authors:  Arthur M Feldman
Journal:  Clin Transl Sci       Date:  2013-08       Impact factor: 4.689

8.  Use of data from registered clinical trials to identify gaps in health research and development.

Authors:  Roderik F Viergever; Robert F Terry; Ghassan Karam
Journal:  Bull World Health Organ       Date:  2013-04-03       Impact factor: 9.408

9.  Compliance with results reporting at ClinicalTrials.gov.

Authors:  Monique L Anderson; Karen Chiswell; Eric D Peterson; Asba Tasneem; James Topping; Robert M Califf
Journal:  N Engl J Med       Date:  2015-03-12       Impact factor: 91.245

10.  Design of non-inferiority randomized trials using the difference in restricted mean survival times.

Authors:  Isabelle R Weir; Ludovic Trinquart
Journal:  Clin Trials       Date:  2018-08-03       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.